Utah Patent of the Month – December 2023
In the realm of pharmaceutical innovation, the cutting-edge developments by SignPath Pharma Inc. are revolutionizing the landscape of drug discovery. A newly patented solution has been designed to prevent drug-induced cardiac events, atrio-ventricular (AV) blocks in particular.
The beating of the heart is controlled by precisely spaced waves of myocardial excitation and contraction. When the spaces between these phases are interrupted, arrhythmias can occur. Some drugs are known to – or even meant to – extend these intervals. However, if it’s not carefully controlled, it can become deadly.
The patent includes a method of treating this drug-induced AV block, or even preventing it. The method involves co-treating the patient with a therapeutic lipid supplement which will reduce the risk of AV blocks brought on by their initial treatment. The specific lipid composition is dependent on the drug the patient is already being treated with. Marketed as CorreQT, the company’s solution has been shown to mitigate cardiomyopathy – a common side effect of chemotherapy. A second, tested application is the prevention of cardiac arrhythmia.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.